RU2019113370A - Комбинация антитела CD19 с ингибитором BCL-2 и пути ее применения - Google Patents
Комбинация антитела CD19 с ингибитором BCL-2 и пути ее применения Download PDFInfo
- Publication number
- RU2019113370A RU2019113370A RU2019113370A RU2019113370A RU2019113370A RU 2019113370 A RU2019113370 A RU 2019113370A RU 2019113370 A RU2019113370 A RU 2019113370A RU 2019113370 A RU2019113370 A RU 2019113370A RU 2019113370 A RU2019113370 A RU 2019113370A
- Authority
- RU
- Russia
- Prior art keywords
- sequence
- seq
- lymphoma
- combination according
- antibody
- Prior art date
Links
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 title claims 6
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 title claims 6
- 239000012664 BCL-2-inhibitor Substances 0.000 title 1
- 229940123711 Bcl2 inhibitor Drugs 0.000 title 1
- 229960001183 venetoclax Drugs 0.000 claims 5
- LQBVNQSMGBZMKD-UHFFFAOYSA-N venetoclax Chemical compound C=1C=C(Cl)C=CC=1C=1CC(C)(C)CCC=1CN(CC1)CCN1C(C=C1OC=2C=C3C=CNC3=NC=2)=CC=C1C(=O)NS(=O)(=O)C(C=C1[N+]([O-])=O)=CC=C1NCC1CCOCC1 LQBVNQSMGBZMKD-UHFFFAOYSA-N 0.000 claims 5
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 3
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 2
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims 2
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 2
- 208000011691 Burkitt lymphomas Diseases 0.000 claims 2
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 2
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 2
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 206010003908 B-cell small lymphocytic lymphoma Diseases 0.000 claims 1
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 201000003444 follicular lymphoma Diseases 0.000 claims 1
- 210000003563 lymphoid tissue Anatomy 0.000 claims 1
- 201000007924 marginal zone B-cell lymphoma Diseases 0.000 claims 1
- 208000021937 marginal zone lymphoma Diseases 0.000 claims 1
- 210000004400 mucous membrane Anatomy 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Endocrinology (AREA)
- Dermatology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Claims (12)
1. Комбинация, содержащая антитело, специфическое в отношении CD19, где указанное антитело содержит область HCDR1, содержащую последовательность SYVMH (SEQ ID NO: 1), область HCDR2, содержащую последовательность NPYNDG (SEQ ID NO: 2), область HCDR3, содержащую последовательность GTYYYGTRVFDY (SEQ ID NO: 3), область LCDR1, содержащую последовательность RSSKSLQNVNGNTYLY (SEQ ID NO: 4), область LCDR2, содержащую последовательность RMSNLNS (SEQ ID NO: 5), и область LCDR3, содержащую последовательность MQHLEYPIT (SEQ ID NO: 6), и венетоклакс, для применения в лечении неходжкинской лимфомы, хронического лимфоцитарного лейкоза и/или острого лимфобластного лейкоза.
2. Комбинация по п. 1, где антитело характеризуется активностью ADCC.
3. Комбинация по п. 1 или 2, где антитело содержит вариабельный домен тяжелой цепи, содержащий последовательность EVQLVESGGGLVKPGG SLKLSCAASGYTFTSY VMHWVRQAPGKGLEWI GYINPYNDGTKYNEKFQ GRVTISSDKSISTAYMEL SSLRSEDTAMYYCARGT YYYGTRVFDYWGQGT LVTVSS (SEQ ID NO: 10), и вариабельный домен легкой цепи с последовательностью DIVMTQSPATLSLSPGER ATLSCRSSKSLQNVNGN TYLYWFQQKPGQSPQL LIYRMSNLNSGVPDRFS GSGSGTEFTLTISSLEPE DFAVYYCMQHLEYPIT FGAGTKLEIK (SEQ ID NO: 11).
4. Комбинация по любому из предыдущих пунктов, где антитело содержит константный домен тяжелой цепи, содержащий последовательность ASTKGPSVFPLAPSSKS TSGGTAALGCLVKDY FPEPVTVSWNSGALTS GVHTFPAVLQSSGLYS LSSVVTVPSSSLGTQT YICNVNHKPSNTKVD KKVEPKSCDKTHTCP PCPAPELLGGPDVFLF PPKPKDTLMISRTPEV TCVVVDVSHEDPEVQ FNWYVDGVEVHNAK TKPREEQFNSTFRVVS VLTVVHQDWLNGKE YKCKVSNKALPAPEE KTISKTKGQPREPQVY TLPPSREEMTKNQVSL TCLVKGFYPSDIAVE WESNGQPENNYKTTP PMLDSDGSFFLYSKL TVDKSRWQQGNVFS CSVMHEALHNHYTQ KSLSLSPGK(SEQ ID NO: 12).
5. Комбинация по любому из предыдущих пунктов, где антитело содержит константный домен легкой цепи, содержащий последовательность RTVAAPSVFIFPPSDE QLKSGTASVVCLLN NFYPREAKVQWKVD NALQSGNSQESVTEQ DSKDSTYSLSSTLTLS KADYEKHKVYACEV THQGLSSPVT KSFNRGEC (SEQ ID NO: 13).
6. Комбинация по любому из предыдущих пунктов, где указанное антитело, специфическое в отношении CD19, и венетоклакс вводятся отдельно.
7. Комбинация по любому из предыдущих пунктов, где венетоклакс вводится до введения антитела, специфического в отношении CD19.
8. Комбинация по любому из предыдущих пунктов, где указанное антитело, специфическое в отношении CD19, и венетоклакс вводятся одновременно.
9. Комбинация по любому из предыдущих пунктов, где указанное антитело, специфическое в отношении CD19, и венетоклакс вводятся в определенный момент времени, при этом оба лекарственных средства проявляют активность у пациента в одно и то же время.
10. Комбинация по любому из предыдущих пунктов для применения в лечении хронического лимфоцитарного лейкоза.
11. Комбинация по любому из предыдущих пунктов для применения в лечении острого лимфобластного лейкоза.
12. Комбинация по любому из предыдущих пунктов для применения в лечении неходжкинской лимфомы, где неходжкинская лимфома выбрана из группы, состоящей из фолликулярной лимфомы, мелкоклеточной лимфоцитарной лимфомы, лимфомы лимфоидной ткани слизистых оболочек, лимфомы маргинальной зоны, диффузной крупноклеточной В-клеточной лимфомы, лимфомы Беркитта и лимфомы из клеток мантийной зоны.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16196184 | 2016-10-28 | ||
| EP16196184.2 | 2016-10-28 | ||
| PCT/EP2017/077654 WO2018078123A1 (en) | 2016-10-28 | 2017-10-27 | Combination of anti cd19 antibody with a bcl-2 inhibitor and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| RU2019113370A true RU2019113370A (ru) | 2020-11-30 |
| RU2019113370A3 RU2019113370A3 (ru) | 2021-03-01 |
| RU2756405C2 RU2756405C2 (ru) | 2021-09-30 |
Family
ID=57218739
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2019113370A RU2756405C2 (ru) | 2016-10-28 | 2017-10-27 | Комбинация антитела CD19 с ингибитором BCL-2 и пути ее применения |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US20190241656A1 (ru) |
| EP (2) | EP3532098B1 (ru) |
| JP (2) | JP7094950B2 (ru) |
| KR (2) | KR102500868B1 (ru) |
| CN (2) | CN118045175A (ru) |
| AU (1) | AU2017348624B2 (ru) |
| BR (1) | BR112019008244A2 (ru) |
| CA (1) | CA3037246A1 (ru) |
| CY (1) | CY1124648T1 (ru) |
| DK (1) | DK3532098T3 (ru) |
| ES (1) | ES2871574T3 (ru) |
| HR (1) | HRP20210838T1 (ru) |
| HU (1) | HUE054496T2 (ru) |
| IL (2) | IL266216B2 (ru) |
| LT (1) | LT3532098T (ru) |
| MX (2) | MX2019004942A (ru) |
| PL (1) | PL3532098T3 (ru) |
| PT (1) | PT3532098T (ru) |
| RS (1) | RS62036B1 (ru) |
| RU (1) | RU2756405C2 (ru) |
| SG (1) | SG10202104036QA (ru) |
| SI (1) | SI3532098T1 (ru) |
| WO (1) | WO2018078123A1 (ru) |
| ZA (1) | ZA201903302B (ru) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3630177T5 (da) * | 2017-05-31 | 2024-09-02 | Morphosys Ag | Behandlingsparadigme til et anti-cd19-antistof og venetoclax-kombinationsbehandling |
| GB201809746D0 (en) * | 2018-06-14 | 2018-08-01 | Berlin Chemie Ag | Pharmaceutical combinations |
| CA3107085A1 (en) * | 2018-08-31 | 2020-03-05 | Adc Therapeutics Sa | Combination of anti-cd19 antibody-pyrroloenzodiazepine conjugate and ve netoclax |
| MX2022005032A (es) * | 2019-10-31 | 2022-07-27 | Morphosys Ag | Terapia secuencial anti cumulo de diferenciacion 19 (cd19). |
| US20220389104A1 (en) * | 2021-05-28 | 2022-12-08 | Ose Immunotherapeutics | Method for Treating CD127-Positive Cancers by Administering an Anti-CD127 Agent |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS60500673A (ja) | 1983-03-08 | 1985-05-09 | コモンウエルス セラム ラボラトリ−ズ コミツシヨン | 抗原活性を有するアミノ酸配列 |
| US5686072A (en) | 1992-06-17 | 1997-11-11 | Board Of Regents, The University Of Texas | Epitope-specific monoclonal antibodies and immunotoxins and uses thereof |
| KR20040023565A (ko) | 2000-09-18 | 2004-03-18 | 아이덱 파마슈티칼즈 코포레이션 | Ｂ 세포 고갈/면역조절 항체 조합을 이용한 자가면역질환의 치료를 위한 조합 요법 |
| DE60226641D1 (de) | 2001-12-03 | 2008-06-26 | Amgen Fremont Inc | Antikörperkategorisierung auf der grundlage von bindungseigenschaften |
| US7902338B2 (en) | 2003-07-31 | 2011-03-08 | Immunomedics, Inc. | Anti-CD19 antibodies |
| EP2216342B1 (en) | 2003-07-31 | 2015-04-22 | Immunomedics, Inc. | Anti-CD19 antibodies |
| JP5215180B2 (ja) | 2005-06-20 | 2013-06-19 | メダレックス インコーポレーティッド | Ｃｄ１９抗体およびその使用法 |
| ES2426468T3 (es) | 2005-12-30 | 2013-10-23 | Merck Patent Gmbh | Anticuerpos anti-CD19 con inmunogenicidad reducida |
| US8524867B2 (en) | 2006-08-14 | 2013-09-03 | Xencor, Inc. | Optimized antibodies that target CD19 |
| WO2008031056A2 (en) | 2006-09-08 | 2008-03-13 | Medimmune, Llc | Humanized anti-cd19 antibodies and their use in treatment of oncology, transplantation and autoimmune disease |
| WO2008150494A1 (en) | 2007-05-30 | 2008-12-11 | Xencor, Inc. | Methods and compositions for inhibiting cd32b expressing cells |
| SI2211904T1 (sl) | 2007-10-19 | 2016-12-30 | Seattle Genetics, Inc. | CD19 vezavna sredstva in njihove uporabe |
| AU2010215239A1 (en) | 2009-02-23 | 2011-09-15 | Glenmark Pharmaceuticals S.A. | Humanized antibodies that bind to CD19 and their uses |
| US8546399B2 (en) | 2009-05-26 | 2013-10-01 | Abbvie Inc. | Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases |
| WO2010151341A1 (en) | 2009-06-24 | 2010-12-29 | The Feinstein Institute For Medical Research | Method for treating chronic lymphocytic leukemia |
| WO2011147834A1 (en) | 2010-05-26 | 2011-12-01 | Roche Glycart Ag | Antibodies against cd19 and uses thereof |
| EP2409993A1 (en) | 2010-07-19 | 2012-01-25 | International-Drug-Development-Biotech | Anti-CD19 antibody having ADCC function with improved glycosylation profile |
| EP2409712A1 (en) | 2010-07-19 | 2012-01-25 | International-Drug-Development-Biotech | Anti-CD19 antibody having ADCC and CDC functions and improved glycosylation profile |
| EP2524929A1 (en) | 2011-05-17 | 2012-11-21 | Sanofi | Use of anti-CD19 maytansinoid immunoconjugate antibody for the treatment of CD19+ B-cell malignancies syptoms |
| SG10201606785UA (en) | 2011-08-16 | 2016-10-28 | Morphosys Ag | Combination therapy with an anti - cd19 antibody and a nitrogen mustard |
| PL2744826T3 (pl) * | 2011-08-16 | 2022-05-30 | Morphosys Ag | Terapia skojarzona przeciwciałem anty-cd19 i analogiem puryny |
| WO2015130585A1 (en) * | 2014-02-28 | 2015-09-03 | Merck Sharp & Dohme Corp. | Method for treating cancer |
| EA201791819A1 (ru) * | 2015-02-12 | 2017-12-29 | Сиэтл Дженетикс, Инк. | Комбинированная терапия с применением конъюгата антитела против cd19 с лекарственным средством и винкристина |
| DK3630177T5 (da) * | 2017-05-31 | 2024-09-02 | Morphosys Ag | Behandlingsparadigme til et anti-cd19-antistof og venetoclax-kombinationsbehandling |
-
2017
- 2017-10-27 PL PL17797564T patent/PL3532098T3/pl unknown
- 2017-10-27 ES ES17797564T patent/ES2871574T3/es active Active
- 2017-10-27 RU RU2019113370A patent/RU2756405C2/ru active
- 2017-10-27 IL IL266216A patent/IL266216B2/en unknown
- 2017-10-27 CN CN202410183851.8A patent/CN118045175A/zh active Pending
- 2017-10-27 SI SI201730811T patent/SI3532098T1/sl unknown
- 2017-10-27 IL IL301786A patent/IL301786A/en unknown
- 2017-10-27 MX MX2019004942A patent/MX2019004942A/es unknown
- 2017-10-27 CN CN201780067047.1A patent/CN109890418B/zh active Active
- 2017-10-27 JP JP2019522273A patent/JP7094950B2/ja active Active
- 2017-10-27 LT LTEP17797564.6T patent/LT3532098T/lt unknown
- 2017-10-27 KR KR1020197012532A patent/KR102500868B1/ko active IP Right Grant
- 2017-10-27 KR KR1020237005018A patent/KR20230028571A/ko not_active Application Discontinuation
- 2017-10-27 PT PT177975646T patent/PT3532098T/pt unknown
- 2017-10-27 RS RS20210792A patent/RS62036B1/sr unknown
- 2017-10-27 CA CA3037246A patent/CA3037246A1/en active Pending
- 2017-10-27 WO PCT/EP2017/077654 patent/WO2018078123A1/en unknown
- 2017-10-27 EP EP17797564.6A patent/EP3532098B1/en active Active
- 2017-10-27 EP EP21165598.0A patent/EP3903821A1/en active Pending
- 2017-10-27 DK DK17797564.6T patent/DK3532098T3/da active
- 2017-10-27 AU AU2017348624A patent/AU2017348624B2/en active Active
- 2017-10-27 HU HUE17797564A patent/HUE054496T2/hu unknown
- 2017-10-27 BR BR112019008244A patent/BR112019008244A2/pt unknown
- 2017-10-27 SG SG10202104036QA patent/SG10202104036QA/en unknown
- 2017-10-27 US US16/342,645 patent/US20190241656A1/en active Pending
-
2019
- 2019-04-26 MX MX2022016270A patent/MX2022016270A/es unknown
- 2019-05-24 ZA ZA2019/03302A patent/ZA201903302B/en unknown
-
2021
- 2021-05-25 HR HRP20210838TT patent/HRP20210838T1/hr unknown
- 2021-06-10 CY CY20211100512T patent/CY1124648T1/el unknown
-
2022
- 2022-06-22 JP JP2022100006A patent/JP2022137089A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20192100T1 (hr) | Kombinacija anti-cd19 antitijela i inhibitora brutonove tirozin kinaze i njene uporabe | |
| RU2019113370A (ru) | Комбинация антитела CD19 с ингибитором BCL-2 и пути ее применения | |
| RU2014103490A (ru) | Комбинированная терапия с помощью антитела к cd19 и аналога пурина | |
| AR110203A1 (es) | Anticuerpos anti-tim-3 para combinación con anticuerpos anti-pd-1 | |
| RU2014103492A (ru) | Комбинированная терапия антителом к cd19 и азотистым ипритом | |
| HRP20231021T1 (hr) | Protutijela anti-cd38 za liječenje akutne limfoblastične leukemije | |
| RU2019112029A (ru) | Применение комбинации антитела к pd-1 и ингибитора vegfr в изготовлении лекарственного средства для лечения злокачественных новообразований | |
| PE20200011A1 (es) | ANTICUERPOS ANTI-PEPTIDO BETA AMILOIDE N3pGlu Y SUS USOS | |
| HRP20210945T1 (hr) | Formulacije protutijela anti-cd19 | |
| JP2017507954A5 (ru) | ||
| JP2022119854A5 (ru) | ||
| HRP20211291T1 (hr) | Kombinacije i njihove primjene | |
| JP2023093495A5 (ru) | ||
| RU2013113933A (ru) | Антитело к cd38 и леналтдомид или бортезомиб для лечения множественной миеломы и nhl | |
| MX2019007848A (es) | Anticuerpos anti-pd-1 y usos de los mismos. | |
| JP2013542194A5 (ru) | ||
| JP2019533682A5 (ru) | ||
| JP2017528462A5 (ru) | ||
| NZ740221A (en) | St2l antagonists and methods of use | |
| JP2017507953A5 (ru) | ||
| JP2013542191A5 (ru) | ||
| AR046677A1 (es) | Formas solidas de anticuerpos anti-egfr | |
| RU2014118741A (ru) | Композиции для лечения ревматоидного артрита и способы их применения | |
| RU2008139602A (ru) | Гуманизированное моноклональное анти-cd20-антитело | |
| PE20141151A1 (es) | Proteinas de union al antigeno cd27l |